Skip to Content
Merck

Y0000492

Oxycodone hydrochloride

European Pharmacopoeia (EP) Reference Standard

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H21NO4 · HCl
CAS Number:
124-90-3
Molecular Weight:
351.82
NACRES:
NA.24
PubChem Substance ID:
329830982
UNSPSC Code:
41116107
MDL number:
MFCD00137583

Product Name

Oxycodone hydrochloride, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

SMILES string

Cl.[H][C@@]12Oc3c(OC)ccc4C[C@H]5N(C)CC[C@@]1(c34)[C@@]5(O)CCC2=O

InChI key

MUZQPDBAOYKNLO-RKXJKUSZSA-N

grade

pharmaceutical primary standard

API family

oxycodone

manufacturer/tradename

EDQM

drug control

USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)
kontrollierte Droge in Deutschland

Gene Information

human ... OPRM1(4988)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Application

Oxycodone hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

μ and κ opioid receptor agonist.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H336

Hazard Classifications

Acute Tox. 4 Oral - STOT SE 3

target_organs

Central nervous system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Caitlin M Vander Weele et al.
The European journal of neuroscience, 40(7), 3041-3054 (2014-09-12)
While most drugs of abuse increase dopamine neurotransmission, rapid neurochemical measurements show that different drugs evoke distinct dopamine release patterns within the nucleus accumbens. Rapid changes in dopamine concentration following psychostimulant administration have been well studied; however, such changes have
Salvatore V Colucci et al.
Clinical drug investigation, 34(6), 421-429 (2014-04-24)
Abuse of opioid analgesics has become a public health issue. Some opioid abusers use intravenous administration to increase the magnitude of positive reinforcing effects. Intravenous co-administration of oxycodone with naloxone, an opioid antagonist, may reduce these rewarding effects and discourage
Carrie L Wade et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(2), 421-428 (2014-07-26)
The abuse of prescription opioids that are used for the treatment of chronic pain is a major public health concern, costing ∼$53.4 billion annually in lost wages, health-care costs, and criminal costs. Although opioids remain a first-line therapy for the
Tomoe Kanbara et al.
Neuroscience letters, 580, 119-124 (2014-08-17)
It has begun to be understood that μ-opioid receptor (MOR) produces ligand-biased agonism, which contributes to differential physiological functions of MOR agonists. We previously demonstrated that in oxaliplatin-induced neuropathy in rats, morphine and oxycodone exhibited antinociceptive effects while antinociception of
Tomohisa Mori et al.
Journal of pharmacological sciences, 126(1), 47-55 (2014-08-22)
The rewarding effects of μ-receptor agonists can be suppressed under several pain conditions. We recently showed that clinically used μ-receptor agonists possess efficacies for relieving the neuropathic pain induced by chemotherapeutic drug in rats; however, it is possible that the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service